{"ranked_hypotheses": [{"title": "Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domain binding", "description": "Rutin engages exposed tau aggregation motifs and lowers early oligomer nucleation, with strongest support expected from cell-free seeding and structural footprinting assays.", "target_gene": "MAPT", "dimension_scores": {"evidence_strength": 0.55, "novelty": 0.72, "feasibility": 0.69, "therapeutic_potential": 0.63, "mechanistic_plausibility": 0.71, "druggability": 0.46, "safety_profile": 0.69, "competitive_landscape": 0.58, "data_availability": 0.67, "reproducibility": 0.57}, "composite_score": 0.627, "evidence_for": [{"claim": "Direct tau anti-aggregation can be resolved with orthogonal biophysics and seeding assays.", "pmid": ""}], "evidence_against": [{"claim": "Polyphenol assay interference and poor CNS exposure could explain false-positive benefit.", "pmid": ""}]}, {"title": "Rutin reduces ROS- and metal-driven tau oligomer nucleation", "description": "Chelation of redox-active metals and suppression of oxidative cross-linking reduce formation of toxic tau oligomers rather than binding mature fibrils directly.", "target_gene": "MAPT", "dimension_scores": {"evidence_strength": 0.51, "novelty": 0.61, "feasibility": 0.75, "therapeutic_potential": 0.57, "mechanistic_plausibility": 0.64, "druggability": 0.48, "safety_profile": 0.71, "competitive_landscape": 0.52, "data_availability": 0.62, "reproducibility": 0.61}, "composite_score": 0.602, "evidence_for": [{"claim": "Metal-sensitive oligomerization assays can directly test the oxidative cross-linking model.", "pmid": ""}], "evidence_against": [{"claim": "Generic antioxidant effects may not explain structural selectivity for pathogenic tau seeds.", "pmid": ""}]}, {"title": "Rutin enhances chaperone and autophagic clearance of misfolded tau", "description": "The compound acts primarily through HSP70 and lysosomal proteostasis pathways, reducing seeded aggregate burden in intact neurons.", "target_gene": "SQSTM1", "dimension_scores": {"evidence_strength": 0.49, "novelty": 0.58, "feasibility": 0.73, "therapeutic_potential": 0.59, "mechanistic_plausibility": 0.63, "druggability": 0.5, "safety_profile": 0.68, "competitive_landscape": 0.55, "data_availability": 0.64, "reproducibility": 0.6}, "composite_score": 0.599, "evidence_for": [{"claim": "Cell-context dependence and pathway inhibition experiments can reveal proteostasis mediation.", "pmid": ""}], "evidence_against": [{"claim": "Without pathway-ablation data this model is too nonspecific to prioritize first.", "pmid": ""}]}], "knowledge_edges": [{"source_id": "MAPT", "source_type": "gene", "target_id": "tau_aggregation", "target_type": "process", "relation": "drives"}, {"source_id": "SQSTM1", "source_type": "gene", "target_id": "tau_clearance", "target_type": "process", "relation": "supports"}], "synthesis_summary": "The debate converged on a split between direct tau binding and indirect proteostasis or redox mechanisms. The most actionable first experiment is a mechanistic cascade that starts with purified tau and then moves into seeded neuronal systems so assay interference can be separated from real biology.\n\nDirect MAPT repeat-domain binding ranked first because it best explains a structure-level effect on oligomer formation, but only if orthogonal assays confirm it at relevant concentrations. Oxidative and proteostasis models remain credible secondary explanations and should be used as falsification branches rather than collapsed into the same mechanism."}